For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

We are availabe to talk to you Monday - Friday 9am - 5pm

GDPR text - this is just a placeholder until correct text is inserted.

Have a member of our team call you back.

GDPR text - this is just a placeholder until correct text is inserted.

You can email us your enquiry by completing the form below.

Donec nisl risus, mattis ut, porttitor vitae, lobortis sagittis, lacus. Nullam neque ligula, congue at, fringilla at, consequat vitae, nulla. Nam ut felis. Curabitur imperdiet ligula a leo molestie malesuada. Praesent neque tortor, placerat accumsan, imperdiet non, iaculis at, mauris. In lacus quam, semper in, ullamcorper et, hendrerit id, pede. Nulla pretium sodales nunc.

Quisque augue quam, pulvinar in, accumsan et, pellentesque sed, ligula. Proin viverra, quam et aliquam molestie, turpis enim pellentesque eros, nec varius sem est id sapien. Aliquam at orci. Cras enim. Nam magna quam, elementum a, aliquet at, eleifend id, lacus. Donec et odio id quam laoreet suscipit.

Quisque ac ante. Aenean in neque. Suspendisse aliquet tincidunt pede. Duis mi. Morbi sapien. Cras posuere interdum nisl. Proin ac eros. Integer sit amet odio. Nullam nec velit dapibus augue condimentum egestas. Phasellus quis odio. Sed semper aliquet risus. Integer gravida vulputate sem. Praesent eu mauris. Fusce consequat congue dui. Vivamus quis metus non dui pellentesque tempor.

Davy Research

Amryt Pharma (AMYT.L, AMYT LN)

Mkt. Cap (£ m):457.3
Shares (m):319.8
Free Float(%):61.1

AMRYT PHARMA
Closing Price (p): 143.0
RATING 14/09/17
OUTPERFORM
PREVIOUS RATING

Allan Smylie CFA

Analyst

Research

Company Profile

Major Shareholders	%
Athytrium Capital Mgmt	14.4
Novelion Therapeutics	8.1
Highbridge Capital Mgmt	7.2
Software AG-Stiftung	6.6
EdgePoint Investment Group	3.7

Davy Research

Jump to

Amryt Pharma (AMYT.L, AMYT LN)

AMRYT PHARMA

RATING 14/09/17

Allan Smylie CFA

Company Profile